The news: Virgin Orbit failed in the first test of its LauncherOne rocket yesterday, after seven years of development and testing. The rocket was transported by a Boeing 747 and released over the Pacific Ocean, off the coast of California. It was supposed to fall for a few seconds, ignite, and then propel itself into low Earth orbit. Instead, it ignited and fell into the sea. The flight had been intended to gather data rather than to actually launch a satellite into space. The crew on board the plane, and a second safety plane, safely returned to the Mojave Air & Space Port.
What happened? On Twitter, the company blamed the crash on “an anomaly” in the first stage flight, promising that “we’ll learn more as our engineers analyze the mountain of data we collected today.” Before the test flight Virgin Orbit’s vice president for special projects, Will Pomerantz, said that there was only a 50-50 chance of success. “History is not terribly kind, necessarily, to maiden flights,” he said. The rocket had previously been dropped from the plane (as in the picture above from July 2019), but this was the first time it was ignited.
What’s next: As Pomerantz said, it is not unusual for maiden flights to fail. It’s not immediately obvious what effect the setback will have on Virgin Orbit. The company has said it is analyzing what went wrong and is “eager” to get onto its next test flight as soon as possible, with rockets in reserve. Pomerantz was upbeat about the company’s chances, saying that the fact the engine had ignited as expected meant it had successfully overcome the “single biggest technical risk.”
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
The dark secret behind those cute AI-generated animal images
Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.